What Is Isoaspartate? The β-Aspartate Backbone Isomer, Explained

Published November 2026 · Patriot Labs Research Team · ~17 min read

The short answer

Isoaspartate — also called isoaspartic acid or β-aspartate — is an isomer of aspartate in which the peptide chain runs through the side-chain carboxyl instead of the normal backbone carboxyl, inserting one extra methylene unit into the main chain and bending it. It forms spontaneously from asparagine or aspartate through a cyclic succinimide intermediate.^[1][2]

What makes isoaspartate worth a guide separate from deamidation is that it is a change to the chain itself, not merely a change to a side group. Two different events feed into it, and both pass through the same five-membered ring: an asparagine can deamidate and land partly as isoaspartate, or an aspartate that was already present can simply isomerise into it without losing anything at all.^[3][6] That second route is strictly mass-neutral, which is the uncomfortable headline of the whole topic: a peptide can carry isoaspartate at the same molecular weight it always had.^[4][6]

The rest of this guide works through that in order — the structural difference that defines the molecule, the two routes and the succinimide they share, why the reaction favours isoaspartate roughly three-to-one, the sequences most prone to it, the repair enzyme PIMT that evolved to recognise it, and finally the analytical methods that can separate an isomer the scale cannot. For the parent reaction, see What Is Deamidation; for the wider catalogue of by-products, Peptide Impurities Explained.

The extra carbon in the backbone

Isoaspartate is best understood by comparison with the residue it comes from. In a normal aspartate (symbol Asp or D), the peptide backbone is built through the residue’s α-carbon and its α-carboxyl group, and the acidic side chain — a short −CH₂−COOH arm — points away from the main chain.^[1] Isoaspartate takes that arm and makes it part of the backbone instead. The chain now passes through what used to be the side-chain carboxyl, and the group that is left dangling is the original α-carboxyl.^[1][3]

The consequence is small on paper and large in practice: one extra methylene (−CH₂−) group is now threaded into the main chain at that point. Because the backbone bond is formed through the β-carboxyl rather than the α-carboxyl, isoaspartate is formally a β-amino acid residue, and the linkage it creates is a β-peptide bond — the reason isoaspartate is often written as β-aspartate.^[1][7] That inserted carbon lengthens the chain by one atom at the residue and introduces a kink, changing the local geometry even though no atoms were gained or lost relative to aspartate.^[3][9]

This structural flip is the source of everything that follows. It is why isoaspartate and aspartate weigh exactly the same yet are genuinely different molecules; why the two can separate on a column when conditions are right; and why nature evolved a dedicated enzyme to find the β-linked residue among its α-linked neighbours.^[3][7] For the underlying anatomy of a normal backbone linkage, see What Is a Peptide Bond; for the broader idea of a residue’s handedness changing on the same skeleton, What Is Racemization.

Two roads in: deamidation and isomerization

Isoaspartate is unusual among peptide alterations in having two separate entrances, and keeping them apart is the key to understanding it. Both roads arrive at the same place by way of the same succinimide ring, but they start from different residues and carry very different mass signatures.^[3][6]

The first road is deamidation of asparagine. Asparagine (Asn, N) carries an amide on its side chain; when that side chain is drawn into the succinimide ring the amide nitrogen leaves as ammonia, and the ring then opens to a mixture of aspartate and isoaspartate.^[1][3] Because an amide (−CONH₂) has become an acid (−COOH), this route carries the familiar deamidation mass increase of about +0.984 daltons, the net of losing an ammonia and gaining a hydroxyl.^[4][6] That small, measurable bump is the subject of the companion guide, What Is Deamidation.

The second road is isomerization of aspartate. Here the starting residue is already an aspartate, so there is no amide to lose. It is drawn into the same ring by dehydration — a loss of water on closing — and when the ring re-opens it, too, yields a mixture that is mostly isoaspartate.^[3][6] Crucially, this route begins and ends as an acid: no net atoms are gained or lost, so the mass change is zero.^[4][6] An aspartate can quietly become isoaspartate with the peptide’s molecular weight unchanged, which is precisely why isoaspartate cannot be ruled out by weighing the molecule.

The practical upshot is that isoaspartate is a broader phenomenon than deamidation alone. A sequence with no asparagine at all can still accumulate isoaspartate at any aspartate it contains, and a stability assessment that watches only for the +0.984 shift will miss it entirely.^[6][10]

The succinimide fork and the three-to-one split

Both roads converge on a single reactive species: a cyclic, five-membered ring called a succinimide (also written aspartyl succinimide or Asu, and sometimes aspartimide). Understanding why isoaspartate dominates means understanding how this ring forms and how it comes apart.^[3][6]

The ring forms when the backbone amide nitrogen of the residue immediately following the asparagine or aspartate folds back and attacks that residue’s side-chain carbonyl carbon.^[3] From an asparagine this expels ammonia; from an aspartate it expels water.^[1][6] Either way the result is the same strained imide ring, which is itself a genuine, detectable intermediate — it has been isolated and tracked as a distinct species in stability studies of therapeutic molecules.^[11]

The fork comes at the next step. The succinimide is unstable to water, and when a water molecule opens the ring it can attack either of the two carbonyl carbons the ring contains. Attack at the original side-chain carbonyl simply undoes the ring back to a normal, α-linked aspartate. Attack at the backbone carbonyl instead leaves the chain running through the side-chain position — isoaspartate.^[3][6] These two openings are not equally likely: hydrolysis favours the backbone position, so the products come out lopsided.^[3][4]

The commonly cited figure is a kinetic ratio of about three parts isoaspartate to one part aspartate, often stated as isoaspartate making up roughly 70 to 85 percent of the hydrolysis products across the systems where it has been measured.^[4][5][6] One electron-capture study of model peptides put the isoaspartate fraction above about 60 percent; a commercial repair-enzyme assay cites a 70 to 85 percent range; and reviews of therapeutic-peptide degradation settle near a three-to-one split.^[4][5][6] The precise number depends on the sequence and the conditions, but the direction never changes: isoaspartate is the majority product every time, which is what makes it the form worth naming.

Which sequences make it fastest

Isoaspartate does not form at the same rate everywhere. The dominant factor is the identity of the residue immediately after the asparagine or aspartate — the so-called n+1 position — because that residue supplies the backbone nitrogen that has to swing round and close the ring.^[3][16] A small, flexible neighbour leaves the site open and lets the ring form easily; a bulky one gets in the way.^[16]

Glycine, the smallest residue, is the classic accelerant. An asparagine–glycine (Asn–Gly) pair is the most notorious fast motif, described as deamidating with a half-life on the order of a day under physiological conditions of about pH 7.4 and 37 °C;^[1] an aspartate–glycine (Asp–Gly) pair is the matching hotspot for the isomerization route.^[6] Serine, also small and able to hydrogen-bond, makes asparagine–serine (Asn–Ser) another reactive pair.^[1][6] At the other end, bulky β-branched residues such as isoleucine, leucine and valine shield the site and slow the reaction by orders of magnitude.^[6]

Two environmental levers sit on top of sequence. Higher pH speeds the succinimide route because it helps deprotonate the attacking backbone nitrogen, while mildly acidic conditions suppress it; and higher temperature accelerates the whole process, which is why cold storage slows it.^[1][6] In a folded protein, higher-order structure can protect an otherwise vulnerable motif by holding the nitrogen out of reach, which is why the same Asn–Gly can be a liability in one molecule and quiet in another; in a short, unstructured research peptide there is little such protection.^[1][3] These are the same levers set out for the parent reaction in What Is Deamidation and How Peptides Degrade. The flagging of such motifs as developability risks is routine enough that liability analyses of large antibody panels catalogue Asn–Gly, Asn–Ser and Asp–Gly sites in the binding regions as a standard screen.^[10][16]

PIMT: the enzyme that reads the mistake

That living systems evolved an enzyme devoted to isoaspartate is the strongest evidence of how routinely it forms. The enzyme is protein L-isoaspartyl O-methyltransferase — abbreviated PIMT and encoded in humans by the gene PCMT1 — and its job is to find isoaspartate residues wherever they have appeared and begin undoing them.^[3][5]

PIMT works by methylation. It transfers a methyl group from the universal donor S-adenosylmethionine (SAM) specifically onto the free α-carboxyl of an isoaspartate, producing a methyl ester and releasing S-adenosylhomocysteine (SAH).^[3][5] That methyl ester is deliberately unstable: it spontaneously decomposes, throwing off methanol and reforming the very same succinimide ring the residue came from.^[5] The ring then re-opens by the same lopsided hydrolysis as before — mostly back to isoaspartate, partly to normal aspartate. Because each pass only converts a fraction, the repair is iterative: PIMT has to methylate the site repeatedly, nudging the population toward normal aspartate over many cycles rather than fixing it in one step.^[3][5]

The biological stakes are real. Studies of PIMT-knockout mice report that animals lacking the enzyme accumulate isoaspartate and suffer fatal epileptic seizures and early death, and work in fruit flies has found that boosting the enzyme extends lifespan, both taken as signs that isoaspartate build-up is damaging and that its repair matters.^[4][14] Proteomic surveys of brain tissue have gone on to catalogue the endogenous proteins PIMT acts on, mapping just how widespread the alteration is in a living system.^[14] None of this applies inside a storage vial, of course: a research peptide on a shelf has no PIMT, so any isoaspartate that forms stays put and simply accumulates — the repair machinery exists only in cells.

The detection problem: an impurity with no mass

Isoaspartate poses a harder analytical problem than most degradation products, and the reason is the one established at the top: in its isomerization form it has the same mass as the aspartate it came from, and even its deamidation form is only the modest +0.984 shift that marks deamidation generally.^[4][6] Intact mass, the workhorse of impurity detection, is essentially blind to the isomer. Worse, ordinary fragmentation does not help much either — collision-induced dissociation produces almost identical b- and y-ion series for aspartate and isoaspartate, so the two look the same in a routine peptide-mapping experiment.^[4] Telling them apart takes methods that interrogate the backbone directly.

Electron-based fragmentation is the mass-spectrometry answer. Techniques such as electron capture dissociation (ECD) and electron transfer dissociation (ETD) cleave the chain by a different chemistry than collisional methods, and they generate fragment ions that are diagnostic of the isoaspartate backbone specifically. A detailed study of model peptides identified a pair of marker ions — an odd-electron c-type fragment heavier by 58 daltons and a complementary z-type fragment lighter by 57 — that appear only when the residue is isoaspartate, arising from a cleavage that runs through the extra backbone carbon isoaspartate uniquely possesses.^[4] Those marker ions let an analyst localise and confirm isoaspartate at a specific site.

Selective digestion offers an orthogonal route. The endoproteinase Asp-N cleaves on the N-terminal side of a normal aspartate but does not cut at an isoaspartate, so a missed cleavage at a site that should have been cut is itself a flag for the isomer; pairing Asp-N digestion with electron transfer dissociation has been developed specifically to pin down isoaspartic acid.^[8] Chromatography and ion mobility add further separations: the kink isoaspartate puts in the chain can change retention on a reversed-phase or ion-exchange column, and gas-phase ion-mobility methods can resolve the isomers by their different collision cross-sections.^[6][13]

Finally, a dedicated enzymatic assay turns the repair enzyme into a detector. A commercial isoaspartate kit uses PIMT and SAM in the test tube: the enzyme methylates whatever isoaspartate is present, and the S-adenosylhomocysteine released — in a one-to-one ratio with the isoaspartate — is measured by reversed-phase HPLC, giving a direct count of total isoaspartate down to roughly ten picomoles.^[5] The trade-off is that the assay reports the global isoaspartate content of a sample rather than which site carries it, so it is often paired with a mass-spectrometry method that supplies the location.^[5][7] Newer labelling approaches continue to refine how cleanly the isomers can be told apart.^[13]

These are the kinds of methods behind a thorough certificate of analysis for a susceptible sequence. Patriot Labs tests every batch at an independent US laboratory by HPLC and mass spectrometry, with the certificate posted on the product page; the general workflow is described in Understanding Peptide COA Testing and Peptide Sequencing Explained.

Isoaspartate in research peptides

For anyone handling research peptides, isoaspartate matters only when the sequence gives it something to work with: an aspartate or an asparagine, ideally followed by a small residue such as glycine or serine.^[1][6] A sequence with neither cannot form it; a sequence with an Asn–Gly or Asp–Gly motif carries a built-in susceptibility that a stability-minded analysis will watch for.^[6][10]

When it does occur, isoaspartate shows up not as a dramatic failure but as a quiet one. Through the isomerization route it leaves the molecular weight untouched, so it can be present in a sample whose intact mass looks perfect; only a backbone-sensitive method reveals it.^[4][6] That is the single most useful thing to carry away: an unchanged mass is not proof that a peptide’s backbone is unchanged. The same storage logic that slows every succinimide reaction applies here — cold, dry, mildly acidic and sealed conditions keep the ring from forming — and those principles are covered as general chemistry, not product instructions, in How to Store Research Peptides and Cold-Chain Peptide Storage.

It is also worth separating the research peptide on a bench from the proteins in the studies cited here. The antibody and brain-protein work exists because isoaspartate is a general feature of aging and stressed proteins; it is quoted here to explain the chemistry and the analytics, not to describe any property of any product.^[3][14]

Isoaspartate next to the neighbouring changes

Isoaspartate sits among a small family of spontaneous backbone and side-chain alterations, and lining them up shows what is distinctive about it. Several share the succinimide intermediate, but they differ in what they change and in whether the mass moves.

Isoaspartate’s signature trait is the one it shares with racemization and not with the others: it can be completely mass-silent. The succinimide is in fact the common hub for three of these at once — the same ring that scrambles aspartate and isoaspartate also opens the door to racemization at that residue, which is why isoaspartate and a D-residue often appear together.^[3][4] Methionine oxidation, by contrast, is a clean mass change at a different atom entirely. The neighbouring chemistry is covered in What Is Deamidation, What Is Racemization and How Peptides Degrade.

What this guide does not establish

This guide is an educational account of the chemistry, biology and analysis of isoaspartate. It describes a naturally occurring and laboratory-studied rearrangement of a peptide chain; it does not describe or recommend any use of any peptide, and nothing here should be read as guidance for use in humans or animals.

A few specific limits are worth stating. The repair enzyme, the knockout-animal findings and the antibody and brain-protein studies described here are results about proteins and enzymes studied in cells, animals, purified systems and formulation research; they are reported strictly as published findings about those molecules and are not outcomes attributed to any product. The ratios, half-lives, mass values and diagnostic-ion shifts are figures from the cited literature, and the exact numbers depend on the peptide, the instrument and the conditions. The storage principles are described only as the chemistry of slowing a succinimide reaction, not as directions for handling or using a product. And this guide makes no claim about the purity, composition or manufacturing of any specific product; those questions are answered by a product’s own certificate of analysis.

Frequently asked questions

What is isoaspartate?

Isoaspartate, also called isoaspartic acid or β-aspartate, is an isomer of aspartate in which the peptide chain runs through the side-chain carboxyl group instead of the usual backbone carboxyl. The effect is to insert one extra methylene (CH₂) unit into the main chain, turning a normal α-linkage into a β-linkage and kinking the backbone. It forms spontaneously in peptides and proteins from asparagine or aspartate by way of a cyclic succinimide intermediate, and it is one of the most studied age- and storage-related alterations of a peptide chain.

What is the difference between aspartate and isoaspartate?

In normal aspartate the chain is connected through the α-carboxyl, and the acidic side chain hangs off to the side. In isoaspartate the connection is flipped: the chain passes through what used to be the side-chain carboxyl, and an extra methylene group sits in the backbone. The two have the same atoms and the same mass, so they are isomers rather than different molecules, but isoaspartate is physically longer and bent at that point, which changes the local shape of the chain. That structural difference is why they can behave differently on a chromatography column and under enzymes even though a mass spectrometer sees one mass.

How does isoaspartate form?

Isoaspartate forms through a cyclic five-membered succinimide intermediate. The backbone nitrogen of the residue just after an asparagine or aspartate attacks that residue’s side-chain carbonyl, closing a ring; asparagine loses ammonia in the process and aspartate loses water. Water then opens the ring again, and it can open at either of two carbonyls. Opening at the original side-chain carbonyl rebuilds normal aspartate, while opening at the backbone carbonyl produces isoaspartate. Because the ring tends to open at the backbone position, isoaspartate is the major product.

Is isoaspartate only a product of deamidation?

No. Isoaspartate has two routes in, and both pass through the same succinimide ring. The first is deamidation, in which an asparagine loses its amide and ends up as a mixture of aspartate and isoaspartate. The second is isomerization of an aspartate that was already there, which needs no deamidation at all and is strictly mass-neutral. This is why isoaspartate is treated as a topic of its own rather than only as a footnote to deamidation: an unchanged peptide mass does not rule it out.

Why is there more isoaspartate than aspartate?

When the succinimide ring is hydrolyzed, water can attack either of the two carbonyl carbons in the ring. Attack at the backbone carbonyl, which yields isoaspartate, is favored, so the two products do not come out evenly. Reported ratios cluster around three parts isoaspartate to one part aspartate, which is often stated as isoaspartate making up roughly 70 to 85 percent of the hydrolysis products. The exact split depends on the sequence and conditions, but isoaspartate is consistently the dominant form.

Can mass spectrometry detect isoaspartate?

Not by mass alone. Isoaspartate and aspartate are isomers with identical mass, so an intact-mass measurement cannot tell them apart, and ordinary collision-induced fragmentation gives nearly identical ion series for both. Distinguishing them takes a method that probes the backbone directly: electron-based fragmentation such as electron transfer or electron capture dissociation produces diagnostic fragment ions unique to the isoaspartate backbone, selective digestion with the enzyme Asp-N leaves a tell-tale missed cut at isoaspartate, and a dedicated enzymatic assay using the repair enzyme PIMT measures total isoaspartate directly.

What is PIMT and does it remove isoaspartate?

PIMT, protein L-isoaspartyl O-methyltransferase (also written PCMT1), is an enzyme found across living systems that recognizes isoaspartate specifically. It transfers a methyl group from S-adenosylmethionine onto the isoaspartate, and that methyl ester spontaneously breaks down and reforms the succinimide ring, which can then re-open toward normal aspartate. Because each cycle only partly converts isoaspartate back, the repair is iterative rather than instant. In living systems PIMT steadily reduces the isoaspartate burden; in a vial on a shelf no such enzyme is present, so any isoaspartate that forms simply accumulates.

Which sequences form isoaspartate fastest?

The single biggest factor is the residue immediately after the asparagine or aspartate. A small, flexible neighbour makes ring closure easy, so asparagine-glycine is the classic fast motif, with aspartate-glycine and asparagine-serine also reactive. Bulkier neighbours such as isoleucine, leucine or valine shield the site and slow it sharply. Higher pH and temperature speed the succinimide route, while mildly acidic, cold conditions slow it, which is why sequence, pH and temperature are all considered together when a peptide’s susceptibility is assessed.

References

1. Wikipedia. Deamidation (asparagine and the succinimide route to aspartate and isoaspartate; Asn–Gly half-life). https://en.wikipedia.org/wiki/Deamidation
2. Geiger, T., & Clarke, S. (1987). Deamidation, isomerization, and racemization at asparaginyl and aspartyl residues in peptides: succinimide-linked reactions that contribute to protein degradation. Journal of Biological Chemistry, 262(2), 785–794.
3. Reissner, K. J., & Aswad, D. W. (2003). Deamidation and isoaspartate formation in proteins: unwanted alterations or surreptitious signals? Cellular and Molecular Life Sciences, 60(7), 1281–1295. https://pubmed.ncbi.nlm.nih.gov/12943218/
4. Cournoyer, J. J., Pittman, J. L., Ivleva, V. B., et al. (2005). Deamidation: differentiation of aspartyl from isoaspartyl products in peptides by electron capture dissociation. Protein Science, 14(2), 452–463. https://pmc.ncbi.nlm.nih.gov/articles/PMC2253403/
5. Promega Corporation. IsoQuant Isoaspartate Detection Kit — Technical Bulletin (PIMT/SAM methylation, SAH quantified by RP-HPLC, 1:1 stoichiometry). https://www.promega.com/resources/protocols/technical-bulletins/101/isoquant-isoaspartate-detection-kit-protocol/
6. ResolveMass Laboratories. Deamidation and Aspartate Isomerization in Therapeutic Peptides (succinimide mechanism, isoAsp:Asp 3:1, sequence hotspots, detection). https://resolvemass.ca/deamidation-and-aspartate-isomerization-in-therapeutic-peptides/
7. Aswad, D. W., Paranandi, M. V., & Schurter, B. T. (1999). Isoaspartate in peptides and proteins: formation, significance, and analysis. Journal of Pharmaceutical and Biomedical Analysis, 21(6), 1129–1136.
8. Ni, W., Dai, S., Karger, B. L., & Zhou, Z. S. (2010). Analysis of isoaspartic acid by selective proteolysis with Asp-N and electron transfer dissociation mass spectrometry. Analytical Chemistry, 82(17), 7485–7491.
9. Yamazaki, Y., et al. (2019). Structural and biochemical basis of the formation of isoaspartate in the complementarity-determining region of antibody 64M-5 Fab. Scientific Reports, 9, 18494. https://www.nature.com/articles/s41598-019-54918-0
10. Deamidation and isomerization liability analysis of 131 clinical-stage antibodies. (2019). mAbs, 11(1), 45–57. https://www.tandfonline.com/doi/full/10.1080/19420862.2018.1548233
11. Comparison of the in vitro and in vivo stability of a succinimide intermediate observed on a therapeutic IgG1 molecule. mAbs (2014). https://pmc.ncbi.nlm.nih.gov/articles/PMC4169036/
12. Analysis of isoaspartate in peptides by electrospray tandem mass spectrometry. Analytical Chemistry (2001). https://www.researchgate.net/publication/12177617
13. Deuterium labeling of isoaspartic and isoglutamic acids for mass spectrometry analysis. (2024). Analytical Chemistry. https://pubs.acs.org/doi/10.1021/acs.analchem.3c05194
14. Protein repair in the brain: proteomic analysis of endogenous substrates for protein L-isoaspartyl methyltransferase in mouse brain. Journal of Biological Chemistry. https://www.jbc.org/article/S0021-9258(20)70560-0/fulltext
15. N+1 engineering of an aspartate isomerization hotspot in the complementarity-determining region of a monoclonal antibody. Journal of Pharmaceutical Sciences (2015). https://jpharmsci.org/article/S0022-3549(15)00185-9/fulltext
16. Tyler-Cross, R., & Schirch, V. (1991). Effects of amino acid sequence, buffers, and ionic strength on the rate and mechanism of deamidation of asparagine residues in small peptides. Journal of Biological Chemistry, 266(33), 22549–22556.

For the neighbouring chemistry, see What Is Deamidation, What Is Racemization and How Peptides Degrade; for the analytical methods behind detection, see What Is Mass Spectrometry and Understanding Peptide COA Testing.

All Patriot Labs products are sold strictly for in-vitro research and laboratory use only. Not for human or veterinary consumption. This guide is educational and describes the chemistry, biology and analysis of isoaspartate in general terms; it is not medical advice, does not describe how to use any product, and makes no claim about the purity, composition or manufacturing location of any specific product.